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C A N C E R
Polyamines drive myeloid cell survival by buffering 
intracellular pH to promote immunosuppression 
in glioblastoma
Jason Miska1*, Aida Rashidi1, Catalina Lee-Chang1, Peng Gao2, Aurora Lopez-Rosas1, 
Peng Zhang1, Rachel Burga1, Brandyn Castro1, Ting Xiao1, Yu Han1, David Hou1, Samay Sampat1, 
Alex Cordero1, Joshua S. Stoolman3, Craig M. Horbinski1, Mark Burns4, Yana K. Reshetnyak5, 
Navdeep S. Chandel3, Maciej S. Lesniak1
Glioblastoma is characterized by the robust infiltration of immunosuppressive tumor-associated myeloid cells (TAMCs). 
It is not fully understood how TAMCs survive in the acidic tumor microenvironment to cause immunosuppression 
in glioblastoma. Metabolic and RNA-seq analysis of TAMCs revealed that the arginine-ornithine-polyamine axis is 
up-regulated in glioblastoma TAMCs but not in tumor-infiltrating CD8+ T cells. Active de novo synthesis of highly 
basic polyamines within TAMCs efficiently buffered low intracellular pH to support the survival of these immuno-
suppressive cells in the harsh acidic environment of solid tumors. Administration of difluoromethylornithine 
(DFMO), a clinically approved inhibitor of polyamine generation, enhanced animal survival in immunocompetent 
mice by causing a tumor-specific reduction of polyamines and decreased intracellular pH in TAMCs. DFMO combi-
nation with immunotherapy or radiotherapy further enhanced animal survival. These findings indicate that poly-
amines are used by glioblastoma TAMCs to maintain normal intracellular pH and cell survival and thus promote 
immunosuppression during tumor evolution.
INTRODUCTION
Glioblastoma (GBM) is an aggressive primary tumor of the central 
nervous system (CNS) that is lethal despite the continuous efforts to 
treat the disease (1, 2). While immunotherapy has become immensely 
effective for most malignancies, for brain tumors it remains dis-
appointing, in part, because of the immune composition of brain 
tumors (3). GBM has an infiltration of tumor-associated myeloid 
cells (TAMCs) and deficiency of T cells that is more robust than any 
other tumor measured (4). TAMCs are a key driver of immuno-
suppression and thus a barrier to successful immunotherapy for glioma 
(5, 6). Recently, there have been large-scale “omics” approaches to 
understand the immunological composition of glioma and how they 
influence patient survival (4, 7, 8). These studies have highlighted the 
importance of myeloid infiltration in glioma and identified targeting 
of the myeloid compartment as a therapeutic strategy for glioma. For 
example, we have recently used a TAMC-targeting system that works 
synergistically with irradiation and chemotherapy to promote survival 
in multiple animal models of the disease (9). Other groups have also 
used other TAMC-targeting approaches/therapies to influence the 
myeloid compartment of brain tumors (10, 11). Moreover, recent 
studies indicate that modulating metabolic pathways can affect 
tumor immunity (12–14).
Brain tumors exist in a harsh environment consisting of severe 
hypoxia (15), extracellular acidification (16–18), and nutrient com-
petition (19, 20). Hypoxia and acidity enhance both cancer aggres-
siveness (21) and immunosuppression (22, 23). Extracellular acidity 
(pHe) causes several immunosuppressive aspects of tumor biology. 
pHe enforces T cell unresponsiveness, and its blockade can promote 
checkpoint immunotherapy for melanoma (24, 25). Furthermore, 
recent work highlighted that pHe can directly enforce the immuno-
suppressive phenotype of macrophages (26). How TAMCs survive 
the acidic tumor microenvironment (TME) is not fully understood 
and is addressed in this study.
RESULTS
TAMCs catabolize arginine to polyamines in brain tumors
To gain insight into this phenomenon, we implanted 7.5 × 104 CT-2A 
glioma cells intracranially into C57/Bl6 mice. After 2 weeks of tumor 
growth, TAMCs were isolated and compared to splenic myeloid cells 
using bulk metabolite analysis by liquid chromatography–tandem 
mass spectrometry (LC-MS/MS; Fig. 1A) and RNA-sequencing 
(RNA-seq) analysis (Fig. 1B). Using a Gr1-based isolation, we 
achieved a high purity (≥89%) of TAMCs from the brain and myeloid 
cells from the spleen (fig. S1, A and B) for our downstream analysis. 
Note that the flow cytometric phenotypes of splenic myeloid cells 
do not significantly differ from those isolated from the blood in regard 
to arginase, PD-L1, and percent Ly6C positivity of the CD45+CD11b+ 
population (fig. S1, C and D). For these reasons, we used splenic 
myeloid cells as a surrogate for probing peripheral myeloid metab-
olism. Unbiased examination of bulk metabolites revealed that TAMCs 
have a significant decrease in arginine with a concomitant increase 
in its downstream metabolites, ornithine, putrescine, and spermi-
dine (Fig. 1A and table S1). Supporting this observation, we found 
that enzymes responsible for the catabolism of arginine into ornithine 
are significantly up-regulated in TAMCs (Tumor Gr1) compared to 
peripheral myeloid cells (Spleen Gr1) (Fig. 1B). Expression of other well- 
established myeloid-derived suppressor cells (MDSCs)/tumor-associated 
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Fig. 1. TAMCs up-regulate the arginine-polyamine axis in brain tumors. (A to C) Mice were implanted with 7.5 × 104 CT-2A tumor cells, and after 14 days of tumor 
engraftment, myeloid cells from the brain (TAMCs) and spleen were isolated via Gr1 magnetic bead isolation and analyzed via LC-MS/MS for metabolomics (A) (table S1) 
and RNA-seq (B). (A) Normalized peak areas of samples were graphed in MetaboAnalyst (74). RNA-seq data were visualized using GSEA heatmap analysis for arginine 
metabolic genes (B). (C) Left: Fpkm values comparing hallmark arginine metabolite genes. Right: Metabolite levels in TAMCs versus peripheral myeloid cells. (D) Flow 
cytometric expression of arginase-1 in matched peripheral versus tumor myeloid cells of both humans and mice. (E) Schematic of the arginine metabolic pathway. (F) In 
vitro generated CD8+ T cells and TAMCs were cultured in 13C-arginine SILAC medium for 2 hours before LC-MS/MS. (G) TAMC and CD8+ T cells were isolated from 
tumor-bearing mice and pulsed ex vivo with 13C-arginine for 2 hours [4 hours in (H)] and analyzed via LC-MS/MS. (A and B) Each replicate is n = 10 mice pooled per sample, 
three independent experiments (a total of n = 30 mice). (C) Five matched human and four matched mouse samples were analyzed for arginase-1 expression. (D) n = 4 
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macrophage (TAM) markers, such as CCR2, PD-L1, and trans-
forming growth factor– (TGF-), was also enriched in TAMCs, 
highlighting the validity of this approach (fig. S2A). GSEA (Gene 
Set Enrichment Analysis) plots generated from RNA-seq data re-
vealed other metabolic pathways up-regulated in TAMCs such as 
fructose, mannose, and galactose metabolism (fig. S2B). There were 
also other metabolic pathways down-regulated in the tumor such as 
nitrogen, glutathione, arachidonic, and purine metabolism (fig. S2C).
Statistical analysis revealed that TAMCs exhibit a 3.27-fold in-
crease in ornithine compared to splenic myeloid cells. There was a 
concomitant decrease in intracellular arginine levels, indicating 
robust arginine catabolism (Fig. 1C). Flow cytometric analysis con-
firmed the up-regulation of arginase-1 in both mouse and human 
TAMCs compared to peripheral myeloid cells (Fig. 1D). This is con-
sistent with previous studies of arginase-1 expression in TAMCs in 
glioma (27, 28). We found minimal evidence of critical urea cycle 
enzymes ornithine transcarbamylase (OTC) and carbamoyl phosphate 
synthetase 1 (CPS1) or their metabolites (citrulline and carbamoyl 
phosphate, respectively) in TAMCs or splenic myeloid cells (fig. S2D).
To validate these observations and to understand whether they 
are myeloid-specific, we first generated TAMCs (9) and CD8+ T cells 
in vitro and performed a 2-hour 13C-arginine relative isotopic in-
corporation. The M+5 incorporation of TAMCs was 76.5 ± 1.2% 
compared to 20.9 ± 0.9% for CD8+ T cells (Fig. 1F), highlighting the 
preferential flux of arginine into ornithine by TAMCs. To confirm 
that this phenomenon occurs similarly in vivo, we performed magnetic 
bead isolation of TAMCs (Gr1) and CD8+ T cells (CD8) from CT-2A 
glioma–bearing mice and performed the same ex vivo 13C-arginine 
relative isotopic incorporation (Fig. 1G). Again, the results show 
that M+5 incorporation of TAMCs was 69.4 ± 3.2% compared to 
3.4 ± 3.4% for CD8+ T cells. These data may suggest that ornithine 
generation is critical to TAMCs in GBM. Considering that the urea 
cycle and inducible nitric oxide synthase (iNOS) activity does not 
appear to be occurring in TAMCs, the only other fate of ornithine is 
its catabolism to polyamines. The rate-limiting enzyme in this pathway 
is ornithine decarboxylase 1 (ODC1), which was highly up-regulated 
in TAMCs (Fig. 1C). A 4-hour ex vivo 13C-arginine relative isotopic 
incorporation revealed that TAMCs robustly generated putrescine 
from arginine, whereas peripheral myeloid cells showed limited ca-
pability (39.5 ± 0.9% versus 9.4 ± 3.4%, respectively) (Fig. 1H).
Polyamines promote myeloid-driven immunosuppression
Considering that TAMCs have a preference for generating putrescine 
from arginine, we analyzed the levels of polyamines in TAMCs com-
pared to CD8+ T cells in Fig. 2A. The normalized peak area levels of 
polyamines, particularly putrescine, were greater than fourfold 
up-regulated in TAMCs (2.2 × 106 ± 1.8 × 105) versus spleens 
(5.6 × 105 ± 1.9 × 105; P < 0.001). Similarly, spermidine levels were 
3.82-fold up-regulated in TAMCs (1.02 × 108 ± 6.4 × 106) versus 
spleens (2.7 × 107 ± 2.5 × 106; P < 0.001). In CD8+ T cells, there was 
a trend toward a decrease of putrescine in tumors (P = 0.1), with 
an increase in spermidine levels in tumors (0.12-fold increase; 
P < 0.05). The role of polyamines in myeloid immunosuppression 
has been addressed previously, as Yu et al. (29) have revealed that 
blockade of de novo polyamine generation using difluoromethylorni-
thine (DFMO) inhibits MDSC-mediated suppression of T cells. To 
determine whether the polyamine pathway is required for immuno-
suppression, we generated TAMCs as previously described (9) and 
performed CD8+ T cell suppressor assays with polyclonal T cells in 
Fig. 2B. At 1:2 and 1:4 TAMC:CD8+ T cells ratios, DFMO pretreatment 
(added immediately upon differentiation at day 0) caused a significant 
decrease in TAMC suppressor functions. LC-MS/MS analysis revealed 
that DFMO pretreatment depletes both putrescine and spermidine 
from TAMCs (fig. S3A). To determine whether this can influence 
antigen-specific responses, we performed the same assay using 
OT-1 CD8+ T cells and SIINFEKL peptide stimulation for 48 hours 
in Fig. 2C. Similar to polyclonal cultures, DFMO pretreatment 
markedly impaired TAMC-induced suppression.
To determine whether DFMO can block polyamine generation 
in vivo, we implanted mice with CT-2A and, after 5 days of tumor 
engraftment (which was sufficient time for tumor establishment as 
verified by neuropathological examination), administered 1% DFMO 
in their drinking water ad libitum. After 7 days of water treatment, 
TAMCs were isolated and compared to splenic myeloid cells using 
LC-MS/MS (Fig. 2D). While splenic myeloid cells showed no changes 
in polyamine content, TAMCs had significant reductions in their 
polyamine content. This suggests that de novo polyamine genera-
tion is required only within the TME. To understand whether this 
reduction is specific to the arginine-ornithine-polyamine axis, we 
performed a 4-hour 13C-arginine relative isotopic incorporation 
ex vivo (Fig. 2E). While there was no difference in the amount of 
13C-labeled ornithine in DFMO-treated animals (suggesting that 
M+5 ornithine incorporation is at steady state), the amount of 
labeled putrescine was almost entirely diminished in the TAMCs of 
DFMO-treated mice (P < 0.001; Fig. 2E). There was no change in 
13C-labeled putrescine in peripheral myeloid cells, supporting a 
tumor-specific phenomenon. To address the possibility of steady-
state labeling, we performed a 13C-arginine metabolite flux analysis 
over multiple time points and found that ornithine flux was reduced 
in DFMO-treated animals at 1 hour (P < 0.001), while it remained 
steady after 2 hours (fig. S3B). Putrescine labeling occurred beginning 
at 4 hours of flux in which DFMO-treated animals never had putres-
cine labeling (fig. S3C). These facts suggest that DFMO treatment 
stymies arginase activity, while it abolishes ODC1 activity. There was 
no change in 13C-labeled urea cycle metabolites, confirming the RNA-
seq and bulk metabolomics data (fig. S4). This suggests that the urea 
cycle/iNOS pathway is inactive in TAMCs in glioma.
We also analyzed the bulk metabolites that significantly changed 
by DFMO treatment in TAMCs (fig. S5) to determine other effects 
of polyamine inhibition. We found a broad array of metabolites 
down-regulated by DFMO treatment that was independent of arginine 
metabolism, such as N-acetylglucosamine, guanosine diphosphate, 
and glutamine (fig. S5A). Some metabolites were increased by DFMO 
treatment, such as 2,3-bisphosphoglycerate, deoxyguanosine, pan-
tothenic acid, and others (fig. S5B). This suggests that polyamine 
inhibition exerts effects beyond just the arginine metabolic pathway.
Polyamine blockade enhances antitumor immunity in GBM
We next sought to understand whether DFMO can be used to pro-
mote animal survival in our murine models of glioma. After 5 days 
of tumor establishment, mice with ad libitum access to 1% DFMO 
drinking water showed a significant enhancement in survival (median 
survival of 20 days in controls versus 33 days in DFMO treatment; 
P < 0.001), as indicated in Fig. 3A. Considering that ODC1 is broadly 
expressed in most brain tumors and inversely correlated with patient 
survival (fig. S6), there is a possibility that inhibition of ODC1 may 
directly influence the growth of tumor, rather than antitumor 
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Fig. 2. Polyamines accumulate in TAMCs in GBM and can be efficiently depleted in vivo. (A) Mice were implanted with 7.5 × 104 CT-2A tumor cells, and after 14 days 
of tumor engraftment, TAMCs were isolated via Gr1 magnetic bead isolation and CD8+ T cells were isolated via CD8+ magnetic bead isolation. (B) In vitro generated 
TAMCs pretreated with DFMO before being cocultured with decreasing ratios of splenic CD8+ T cells labeled with CellTrace Violet dye. (C) The same assay was performed 
using OT-1 T cells stimulated with SIINFEKL peptide. Forty-eight (C) and 72 (B) hours after coculture, T cell proliferation was analyzed via flow cytometric analysis. (D and 
E) Mice were implanted with 7.5 × 104 CT-2A tumor cells, and after 5 to 6 days of tumor engraftment, 1% DFMO water was supplied ad libitum to experimental mice. After 
7 days of DFMO water treatment, TAMCs were magnetically isolated for bulk metabolomics (D) or pulsed in vitro with 13C-arginine for 4 hours before metabolite isolation 
(E). (F) Schematic overview of polyamine metabolism. (A, D, and E) Each sample is n = 8 to 10 mice pooled per sample, three pooled samples per group. (B and C) Suppressor 
assays were carried out with n = 3 per each ratio tested, representative of two independent experiments. All statistics in this figure were analyzed by unpaired Student’s 
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survival experiment in RAG-1 knockout (KO) mice (lacking T and 
B cells) and found a minimal change in the survival of mice (median 
survival of 16 days in controls versus 19 days in DFMO treatment; 
P < 0.001) (Fig. 3B). This strongly supports the hypothesis that 
DFMO perturbs the immunosuppressive microenvironment of glioma, 
not glioma cells themselves. Flow cytometric analysis demonstrated 
that the myeloid compartment (including microglia) in the tumor 
of DFMO-treated RAG-1 KO mice significantly up-regulates tumor 
necrosis factor– (TNF; fig. S7A), while other cytokines were un-
affected. Notably, after 1 week of DFMO treatment in immuno-
competent animals, a significant reduction in the myeloid:CD8+ 
T cell ratio was observed as shown in Fig. 3C. Consistent with our 
metabolic data, DFMO appears to specifically target M-MDSCs 
(monocytic MDSCs)/monocytes, microglia, and TAMs in the tumor, 
as PMN-MDSCs (polymorphonuclear MDSCs)/neutrophils and all 
measured T cell subsets were unaffected (Fig. 3D). DFMO treatment 
caused a significant reduction in arginase-1 expression within the 
M-MDSC/monocyte compartment, suggesting that DFMO causes 
perturbation of the entire arginine metabolic pathway (Fig. 3C). 
The gating strategy of this analysis can be found in fig. S8 (A and B). 
To validate the flow cytometric data, immunofluorescence was per-
formed on tumor tissues harvested from control and DFMO-treated 
mice (Fig. 3, E and F). Our data, again, show a significant decrease 
in CD11b+ cells (P < 0.04) and CD11b/CD8 ratio (8.1 ± 0.7 in con-
trols compared to 2.4 ± 0.3 in DFMO-treated brains; P < 0.001) in 
the tumor with a concomitant increase in CD8+ cells (19 ± 2 cells 
per 20× field in controls compared to 49 ± 4.6  in DFMO-treated 
brains; P < 0.001).
DFMO administration in another syngeneic model of glioma 
(GL-261) also revealed a significant improvement in animal survival 
(fig. S9A). In this model, we observed a survival benefit (median 
survival of 20 days in control and 24 days in DFMO treatment; 
P < 0.05; fig. S9A), a reduction of TAMC/T cell ratios (P < 0.07; 
fig. S9B), a down-regulated arginase expression (P < 0.01; fig. S9C), 
and a lower abundance of M-MDSC/monocytes (P < 0.05; fig. S9E) 
with DFMO administration. Marked differences were observed be-
tween the two models. In GL-261 model, there were significant in-
creases in CD8/CD4 ratio with DFMO administration (0.8 ± 0.05 in 
controls compared to 1.3 ± 0.14 in DFMO-treated brains; P < 0.01; 
fig. S9D), while we did not observe differences in microglial popula-
tions (fig. S9E). This suggests that there might be a model-to-model 
variation in the way polyamine blockade influences anti-GBM 
immunity; TAMC perturbation is a common effect.
Polyamines are ubiquitous in nature and have been ascribed to 
many roles in cells. A seminal study shows that polyamines are re-
quired for the proliferation of all mammalian cells (31). To this end, 
we sought to determine whether TAMCs are generating polyamine 
to fuel their intratumoral proliferation (Fig. 3G). While there was 
no change in the Ki-67 expression in TAMCs, Ki-67 was significantly 
up-regulated in T cell subsets measured in the brain of DFMO-treated 
mice (P < 0.05). However, there was no change in cytokine expres-
sion in T cells of DFMO-treated animals, suggesting that other mech-
anisms of immunosuppression were still functional in these mice 
(fig. S8, C and D). We observed that although pretreatment with 
DFMO decreased TAMC/T cell ratios in vivo, it largely up-regulated 
the expression of PD-L1 on TAMCs in vivo (Fig. 4A) and in vitro 
(Fig. 4B). Supplementation of TAMCs with exogenous putrescine 
was able to rescue this up-regulation. This suggests that checkpoint 
molecules are still functioning in the context of DFMO treatment. 
To understand whether DFMO can be used to potentiate immuno-
therapy, we administered anti–PD-L1 therapeutic antibody together 
with DFMO treatment in mice and found an additive effect on ani-
mal survival (median survival of 26 days in anti–PD-L1 treatment, 
30 days in DFMO treatment, and 45 days in the combination group; 
P < 0.001) (Fig. 4C). Combinatorial therapy using anti–PD-1 also 
increased animal survival (Fig. 4D). As previous work has shown 
that polyamines can protect GBM from the antitumor effects of 
radiotherapy (32), we also treated mice with DFMO and radiotherapy 
(3 Gy × 3 days), which also resulted in combinatorial survival bene-
fit in mice (Fig. 4E). As the CT-2A model is normally resistant to 
checkpoint blockade, these data highlight the importance of myeloid 
cells in promoting the efficacy of both checkpoint immunotherapy 
and radiotherapy. To examine the immunological effects of combi-
natorial therapy, we implanted mice with GL-261 tumors overex-
pressing ovalbumin (OVA) and followed up with treatment of anti–
PD-L1, DFMO, or combination starting at 1 week after implantation. 
One week after therapeutic administration, using tetramer staining, 
we found an increase in OVA-specific T cells within the tumors of 
combinatorial-treated animals (P < 0.05; Fig. 4, F and G). This sug-
gests that DFMO and checkpoint administration promotes antigen- 
specific T cell recruitment to brain tumors.
Polyamines buffer the intracellular pH of TAMCs
We next sought a mechanistic understanding as to why TAMCs have 
a preference for generation of polyamines in brain tumors. We 
explored the possibility that as polyamines are highly basic com-
pounds (33), perhaps they are playing a role in TAMC survival in 
the acidic and hypoxic glioma microenvironment. To determine 
whether this brain tumor model has an acidic environment, we im-
planted mice with CT-2A tumors and, 14 days after engraftment, 
injected mice intravenously with the extracellular pH-sensing probe 
pHLIP (pH-low insertion peptide) labeled with fluorescent dye 
Cy5.5 (pHLIP-Cy5.5) and compared to mice without tumors (Fig. 5A). 
The pHLIP probe only inserts into the membrane of cells within 
acidic extracellular environments, while it will wash out of pH neutral 
tissues (34). IVIS imaging demonstrated a strong signal only within 
tumor-bearing brains but minimal detection in nontumor brains 
(2.03 × 107 ± 8.14 × 106 versus 1.3 × 106 ± 2.22 × 105 maximum 
radiance in tumors compared to controls, respectively; P < 0.001) or 
spleens. This shows that brain tumors generate an extracellular 
acidic milieu.
We next determined whether polyamines endow TAMCs the ability 
to survive under conditions of pHe (Fig. 5, B and C). To test this 
hypothesis, we generated TAMCs in vitro and then cultured for ad-
ditional 48 hours under pH 6.7 condition. Unexpectedly, DFMO 
pretreatment caused significant necrosis of TAMCs in the context 
of acidity but not controls (21.1 ± 1.62% versus 2.2 ± 0.36%, re-
spectively; P < 0.001). To highlight that polyamines are critical for 
preventing intracellular acidity–induced cell death, we added putres-
cine back to our TAMC cultures during DFMO treatment, which 
was able to rescue TAMC cell death under conditions of pHe. To 
observe this phenomenon in vivo, we treated mice with DFMO and 
performed flow cytometry using the pH-sensitive dye pHrodo to 
measure intracellular pH in TAMCs. pHrodo Red AM dye is taken 
by cells and activated by low pH, of which the fluorescence intensi-
ty increases along with the decreased pH (35). Measurement of 
normalized pHrodo revealed a significant increase of fluorescence 
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Fig. 3. Polyamine depletion promotes T cell–driven antitumor immunity in GBM. C57/Bl6 (A) or RAG10/0 (B) mice were implanted with 7.5 × 104 CT-2A tumor cells, 
and after 5 to 6 days of tumor engraftment, 1% DFMO water was given. Animal survival was then measured and graphed. (C and D) Mice were implanted with 7.5 × 104 
CT-2A, administered DFMO ad libitum at day 5, and analyzed via flow cytometry 5 days after DFMO treatment. (C) Ratio of myeloid to T cells; monocyte expression 
of arginase-1 was calculated. (D) Absolute numbers of myeloid and T cell subpopulations in CT-2A tumor–bearing animals with or without DFMO administration. 
(E and F) Brains from controls or mice treated with DFMO were harvested and flash-frozen before immunofluorescence was performed using CD11b– Alexa Fluor 488 and 
CD8-PE. (G) Ki-67 expression of all major immune subsets in the tumor compared to the spleen of tumor-bearing mice treated with 1% DFMO in their drinking water 
as in (C) and (D). (A and B) n = 10 mice per group were used (5 male and 5 female per group, all age-matched at 6 to 8 weeks of age), representative of four experiments 
in (A) and two experiments in (B). (C, D, and G) n = 4 to 5 mice per group were analyzed and are representative of two independent experiments for each panel. (F) n = 4 
mice per group were blindly counted for cellular infiltration. (A and B) Significance was calculated using log-rank analysis followed by Bonferroni correction. (C, D, F, 
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occur in the spleen (Fig. 5D). Accordingly, the mean fluorescence 
intensity (MFI) of pHrodo was significantly increased in TAMCs of 
DFMO-treated mice (1788 ± 157 arbitrary units in control versus 
2179 ± 53 DFMO treated; P < 0.05) (fig. S9F), indicating that poly-
amines are generated within TAMCs to maintain normal intracellular 
pH and promote survival within the acidic TME. We further val-
idated these findings by generating TAMCs in vitro under DFMO 
or DFMO  +  putrescine supplementation, labeled them with 
pHrodo, and monitored fluorescence change under acidic pHs 
over time using the IncuCyte imaging platform (Fig. 5, E and F). 
Comparison of treatments across lowering pH revealed that DFMO 
significantly promotes intracellular acidity in TAMCs that is res-
cued by putrescine pretreatment (Fig.  5F). Thus, TAMCs treated 
with DFMO are unable to maintain a neutral intracellular pH under 
acid stress, whereas controls and putrescine rescue could better handle 
acid stress. Excessive acidification hinders glycolytic metabolism. 
Fig. 4. Polyamine inhibition promotes multiple different therapies for GBM. (A) Mice were implanted with 7.5 × 104 CT-2A, pretreated with DFMO, and analyzed for 
PD-L1 MFI expression. (B) TAMCs were generated in vitro in the context of DFMO or DFMO + putrescine, and PD-L1 expression was analyzed after 7 days of differentiation. 
(C) The same DFMO schema was used in combination with anti–PD-L1 treatment (or treated with monoclonal antibody alone), and animal survival was measured. 
(D) Seven days after tumor implantation, mice were treated with anti–PD-1 (every 3 days, 10 mg/kg) or combination therapy, and survival was analyzed. (E) Seven days 
after tumor implantation, mice were treated with DFMO, 3 × 3-Gy irradiation (IR), or combination. (F and G) GL-261 (2 × 105) overexpressing OVA were implanted intracra-
nially into mice that were then treated with PD-L1, DFMO, or combinatorial treatment. Brains were harvested and stained for tetramer positivity. (A and B) Data are n = 3 
per group representative of two independent experiments. Survival curves were performed n = 8 (C) and n = 10 (D and E) mice per group. Five male and five female mice 
per group were analyzed in (D) and (E); n = 4 per gender in (C), all age-matched at 6 to 8 weeks of age. (F and G) n = 5 per group were analyzed. Significance in (C) to (E) 
was calculated using log-rank analysis followed by Bonferroni correction. Significance in (A) and (B) and (F) and (G) was calculated by one-way analysis of variance (ANOVA), 
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Fig. 5. Polyamines promote the metabolism and survival of TAMCs by regulating acidic stress produced by the tumor microenvironment. (A) Mice were implant-
ed with tumors or phosphate-buffered saline (PBS) and, after 14 days, injected with 100 M pHLIP-Cy5.5 dye via intravenous injection. Twenty-four hours after injection, 
brains and spleen were quantified using a spectral imaging system. (B and C) TAMCs were generated in the context of DFMO or in DFMO with exogenous putrescine. 
After 6 days of differentiation, cells were lifted and replated into complete RPMI buffered to an acidic pH. Forty-eight hours after replating, flow cytometric analysis was 
performed to determine apoptosis/necrosis of TAMCs. (D) Spleens and tumor-infiltrating lymphocytes from controls or DFMO-treated animals were stained with pHrodo 
Red AM intracellular pH dye. (E) Intracellular pH was determined by generation of pH standard curve. RCU, red calibrated unit. (F) TAMCs were generated under control 
conditions and pretreated with DFMO or DFMO + 100 M putrescine added. After 6 days, cells were washed and labeled with pHrodo Red AM dye. IncuCyte analysis was 
then performed to monitor intracellular acidity over time. After 2 hours of measurement, nigericin/valinomycin was added. n = 4 wells per group, representative of three 
independent experiments. (A) n = 4 control and tumor-bearing brains/spleens were analyzed. (B to D) n = 3 per group, representative of two independent experiments. 
Significance was calculated via unpaired Student’s t tests (A and D) and one-way ANOVA with Tukey’s post hoc for individual comparisons in (C) and (F): 
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This occurs because proton/CO2 extrusion is needed to maintain in-
tracellular pH during glycolysis (36–38). This has been recently 
shown as a method by which T cells hinder their own effector func-
tions (39). As tumors tend to use extensive glycolytic metabolism, 
this may be why atypical proton extruders carbonic anhydrases IX 
and XII are up-regulated in solid tumors (40, 41). Therefore, it is possi-
ble that polyamines are generated within TAMCs to facilitate intracellu-
lar pH normalization and, thus, glycolytic metabolism.
To test this, we generated TAMCs with or without DFMO in vitro, 
cultured the cells under decreasing pHs, and performed extracellular 
flux analysis using Seahorse analysis (Fig. 6A). Under all conditions 
of reducing pH, both control and DFMO pretreated samples had 
a significant reduction in ECAR (extracellular acidification rate) 
(P < 0.001 for all comparisons within groups at each pH). When com-
paring across treatments, basal ECAR was reduced in DFMO-treated 
TAMCs under all pHe (pH 7.4: 69.1 ± 2 mpH/min in control versus 
35.0 ± 3.7 mpH/min in DFMO pretreated; pH 7.0: 51.0 ± 1 mpH/min 
in control versus 26.0 ± 0.8 mpH/min in DFMO pretreated; pH 6.7: 
30.6 ± 0.7 mpH/min in control versus 20.0 ± 1.3 mpH/min in DFMO 
pretreated; P < 0.001). Furthermore, both glucose-stimulated ECAR 
and maximal ECAR were significantly reduced by DFMO pretreat-
ment at pH 7.4 and 7.0 (P < 0.001). At pH 6.7, differences between 
DFMO and control groups were not observed, suggesting a limitation 
to the buffering capacity of polyamines in this system.
Last, to determine whether metabolic perturbation of TAMCs 
occurs in the context of glioma, we performed TAMC isolation and 
performed 13C-glucose flux analysis from CT-2A tumor–bearing 
animals (Fig. 6B). DFMO-pretreated animals had significantly re-
duced glycolytic metabolism as shown by reduced M+3 pyruvate 
(44.6 ± 3.8% in control versus 10.2 ± 4.6% in DFMO treated; P < 0.01) 
and lactate incorporation (1.9 ± 0.2% in control versus 1.0 ± 0.13% in 
DFMO treated; P < 0.05). Using an in vivo carbon flux model (42), we 
assessed 13C-glucose flux in vivo in control and DFMO-treated ani-
mals to look at bulk tumor 13C-glucose flux (Fig. 6C). While there was 
enhanced M+3 lactate incorporation by the bulk TME compared to 
the liver (52.5 ± 2.3% in tumor versus 20.7 ± 3.2% in the liver; P < 0.01), 
there was no change in the bulk tumor glycolytic metabolism of DFMO- 
treated animals. This final observation highlights the specificity of 
DFMO on blunting TAMC immunosuppression in GBM.
DISCUSSION
Arginase-1 expression has been considered a hallmark of the sup-
pressive myeloid phenotype for the past 20 years (43, 44). Alongside 
these observations, many studies have shown that the catabolism of 
the argainse-1 metabolite, ornithine (via ODC1), broadly promotes 
the immunosuppression of myeloid lineage cells (29, 45, 46). 
Supporting the importance of polyamine generation in myeloid 
function, a recent critical study revealed that macrophages generate 
polyamines to support the alternative activation of macrophages via 
the hypusination of EIF5 (47). While there is abundant evidence 
that this pathway is important for myeloid cell to induce immuno-
suppression, the mechanism why this metabolic pathway is invoked 
has yet to be understood. Our results provide a potential metabolic 
explanation whereby the generation of the polyamine putrescine acts 
as pH buffer against hostile acidic TME to promote both the survival 
and metabolic functions of TAMCs in GBM.
Immunosuppressive or “inflammation-resolving” myeloid cells 
must enter an inflamed tissue to exert their effects. Both tumor 
tissues and inflamed tissues are hypoxic (48) and, by extension, 
acidic (49, 50). The ability of cells to function or survive under such 
intense environmental stress likely underlies their ability to halt an 
ongoing immune response. This appears to be particularly important 
in the context of glioma, as we identified via unbiased methods that 
arginine metabolism is a central metabolic tenet of TAMCs in 
GBM. This comports with a seminal study on the function of arginase-1 
myeloid-driven immunosuppression in cancer (51). We found that 
not only was the arginase-1 pathway involved in the generation of 
ornithine in TAMCs but so was the de novo creatine pathway [via 
Glycine amidinotransferase (GATM)], which also generates orni-
thine. Our results also highlighted that the fate of arginine in TAMCs 
is directed toward polyamine generation and not the iNOS pathway, 
although myeloid cells are known to use this pathway for immuno-
suppression in other malignancies (52). One potential explanation is 
the preponderance of M-MDSCs in both human and murine models 
of glioma (9, 53). As PMN-MDSCs are recognized as the major pro-
ducer of iNOS-mediated immunosuppression (54), it may be particu-
larly relevant to look at myeloid-polyamine metabolism in the context 
of GBM. Why the metabolic phenotype of TAMCs differs so marked-
ly from peripheral myeloid cells is likely a result of predominate 
migration and accumulation of MDSC in gliomas (53), intratumoral 
proliferation of myeloid cells (55), or cues that come from the TME 
(56). How these cues influence metabolic phenotypes is unknown and 
an important topic for future exploration. While this study was fo-
cused mainly on TAMCs, microglial populations were also affected 
by DFMO administration, suggesting that microglia may also play a 
role in the inflammatory responses to polyamine blockade.
Our second observation is that the polyamine metabolic pathway 
is critical for TAMC-mediated immunosuppression in GBM. The 
importance of polyamine anabolism on TAMC function is consistent 
with the aforementioned studies on the importance of the polyamine 
pathway in the maintenance of M2 myeloid lineage cells. The mech-
anistic insights into these observations were mainly attributed to 
changes in gene expression (29) or epigenetic status of the cells 
(45, 46). We did find that DFMO might exert its role by up-regulating 
TNF, a proinflammatory cytokine seen up-regulated in ODC con-
ditional KO mice (45). Further work is needed to understand how 
polyamine influences inflammatory gene expression.
Our third observation is that blockade of de novo polyamine 
generation via DFMO is therapeutically relevant for murine models 
of GBM. It is unexpected that monotherapy with DFMO caused in-
creased animal survival in immunocompetent animals, which was 
abrogated in the immunodeficient model of the disease (57). As our 
data showed that significant survival benefit with DFMO was abro-
gated in RAG-1 KO mice, this indicates that DFMO functions via 
promotion of antitumor adaptive immune responses. This result 
highlights the importance of the de novo polyamine pathway on 
immunity that is compartmental in nature. The immunologic con-
sequences of polyamine inhibition are still relatively unknown, but 
our work shows that myeloid cells are likely the primary target of 
such therapy. We saw that treatment with DFMO increased PD-L1 
expression in the TME, which has been recently used as an indica-
tor of increased inflammation in glioma (58). For this reason, we 
believe that targeting the PD–PD-L1 pathway will further enhance 
adaptive immune response by blocking T cell exhaustion (59). We 
found that polyamine inhibition can work in concert with T cell–
based immunotherapies for this disease. The mechanisms behind 
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Unfortunately, polyamine inhibition has not yet yielded significant 
benefits in the clinic (60). This is similar to clinical experience with 
immunotherapies (61), and the reasons for this are currently un-
known. Recent work has shown that steroid administration and 
standard-of-care therapies, both of which are frequently given to 
patients, can potently inhibit antitumor immune responses (62, 63) 
and may play a role in treatment resistance, but more work is need-
ed to understand these interactions.
A caveat of these treatment modalities is that they did not elicit 
long-term survival benefit. The reasons for this are unknown, but 
considering that T cells undergo significant metabolic programming 
at different stages of activation/memory (64), it is possible that 
de novo polyamine generation is important for an immunological 
memory phenotype or some other unknown processes critical for 
long-term antitumor immunity. In the future, it will be critical to 
uncover when polyamine generation is needed for T cells and why. 
Related to this point is that polyamines can be acquired exogenously. 
The ability of cells to complement de novo polyamine generation 
with exogenous uptake has inspired compounds that inhibit poly-
amine uptake (65). There are currently a number of clinical trials 
focused on this combinatorial modality. As the uptake inhibitors have 
very limited accessibility to the CNS, future work will be focused on 
understanding whether we can deliver this next-generation polyamine 
therapeutics to patients with GBM.
Our last observation is that polyamines act as an intracellular pH 
buffer that promotes both the survival and metabolic functions of 
TAMCs in GBM. Polyamines are incredibly basic compounds, which 
were initially discovered as the major constituent of semen (66). 
This acidic environment is recapitulated in solid tumors, and our 
data show that TAMCs generate their own basic metabolites to sur-
vive under these harsh conditions. This phenomenon is not without 
precedent, as a previous study showed that polyamine blockade in-
duces intracellular acidification in leukemic cells (67). Many tumors 
are known to up-regulate polyamine generation, which is why studies 
have argued that polyamines are immunosuppressive compounds 
(65, 68). Our data, however, suggest that the presence of polyamines 
Fig. 6. Polyamines promote the metabolism of TAMCs under conditions of pHe. (A) TAMCs were generated in the context of DFMO, and after 6 days of differentiation, 
cells were lifted, adhered using Cell-Tak adhesive, and cultured in decreasing pH medium. Immediately following addition of acidic medium, Seahorse extracellular flux 
analysis was performed to determine glycolytic metabolism. (B) DFMO-treated animals had TAMCs isolated, and ex vivo 13C-glucose flux was performed. (C) In vivo 
13C-glucose flux was performed by infusion of 13C-glucose (100 mg/ml) over a 2.5-hour period. After infusion, tumor, adjacent parenchyma, and liver were flash-frozen for 
bulk metabolite analysis. (A) n = 5 per group, representative of two independent experiments. (B) Each sample is n = 10 mice pooled per sample, with three pooled sam-
ples submitted in triplicate; data are representative of two independent experiments. (C) n = 3 mice were individually analyzed per group. Statistics were calculated via 
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is actually a survival mechanism for cells. Perhaps endowing T cells 
with an enhanced ability to generate their own polyamines may actually 
be beneficial for their function in tumors. As both glycolytic and 
mitochondrial metabolism generate a large amount of acidic end 
products, we have also observed that de novo polyamine generation 
also maintains intracellular pH and, thus, metabolic fitness of TAMCs. 
Note that whole-tumor glucose flux did not reveal the same changes 
induced by DFMO treatment on TAMCs, further highlighting the 
specificity of the de novo polyamine pathway on this immunosup-
pressive subset.
In summation, this work shows that polyamine metabolism is a 
central tenet of immunosuppression in GBM that can be targeted 
effectively. This lays groundwork for future studies to understand 
the exact roles that polyamines have on different glioma-infiltrating 
cellular subsets and how we can use them to promote antitumor 
immunity for this untreatable disease.
MATERIALS AND METHODS
Mouse models
All mice were housed at the Center for Comparative Medicine at 
Northwestern Feinberg School of Medicine. Mice are all housed in 
a conventional barrier facility with 12-hour light/12-hour dark 
cycles and ad libitum access to food and water. C57/Bl6, OT-1 Bl6, 
and RAG0/0 Bl6 mice were obtained from The Jackson Laboratory 
(Bar Harbor, ME) and bred for use in experiments. All experiments 
were performed in mice 6 to 8 weeks old, age- and gender-matched. 
Equal numbers of male and female mice were used whenever possi-
ble. For all Kaplan-Meier curves, C57/Bl6 mice were purchased at 
6 weeks old, and numbers of male/female mice were always equiva-
lent between control and experimental groups. All mouse protocols 
performed in this study were approved by Northwestern’s Institu-
tional Animal Care and Use Committee under study approval 
number IS00002459.
Cell lines and tumor implantation
The CT-2A tumor line was initially obtained from T. Seyfried (Boston 
College). The GL-261 tumor line was purchased from the National 
Cancer Institute (NCI). Cells were cultured in Dulbecco’s modified 
Eagle’s medium (Corning) supplemented with 10% fetal bovine 
serum (FBS; HyClone) and penicillin-streptomycin. For injections, 
cells were lifted with trypsin-EDTA (Corning), washed with phosphate- 
buffered saline (PBS), and suspended at a concentration of 7.5 × 104 cells 
(1.0 × 105 for GL-26 and 2 × 105 for GL-26–OVA) per 2.5 l. Mice 
were implanted with CT-2A using a stereotactic apparatus follow-
ing the exact specifications as described previously (69). Following 
this method, tumor cell injection has a 100% engraftment rate in 
C57/Bl6 mice. GL-261 lines overexpressing OVA were generated 
previously (70) and cultured in G-418 (200 g/ml; Sigma-Aldrich) 
to maintain selection pressure.
Tissue and cellular isolations
Mice
Tumor-bearing mice were perfused with 1× PBS before tumors were 
removed and homogenized in Hanks’ balanced salt solution (Gibco, 
Thermo Fisher Scientific) using a Dounce homogenizer (Sigma- 
Aldrich). Homogenized tissues were passed through a 70-m filter, 
spun, and then resuspended in 30% Percoll (GE Healthcare) layered 
carefully over 70% Percoll solution for density gradient centrifuga-
tion as performed previously (69). Interface was collected and washed 
in PBS before any downstream analysis. For splenic isolation, spleens 
were directly homogenized though a 70-m strainer, followed by 
red blood lysis using ACK buffer (Gibco, Thermo Fisher Scientific). 
Cells were washed and then used for all downstream analysis.
Humans
Fresh tumor tissue was harvested from newly diagnosed GBM 
patients, manually diced with a sterile scalpel, and incubated with 
collagenase/deoxyribonuclease 1 (DNase 1)/ Tosyl-l-lysyl-chloromethane 
hydrochloride (TLCK) (all Sigma-Aldrich) mixture for 15-min intervals 
at 37°C. Once tissue was digested, it was homogenized and leukocytes 
were isolated via Percoll gradient centrifugation as described for mouse 
tumor isolation. For peripheral blood mononuclear cell (PBMC) isola-
tion, blood was isolated from matched patients and leukocytes were 
isolated via Ficoll-Paque ® PLUS (GE Healthcare) density gradient centrif-
ugation. PBMCs were washed and used for all downstream analysis.
Magnetic bead isolation of cells
To isolate specific populations of cells, single-cell suspensions as 
isolated above are preblocked with anti-CD16/32 for 15 min at 
4°C. We then used the biotinylated anti-Gr1 (clone RB6-8C5), anti- 
CD8, or anti-CD163 antibodies (all from Thermo Fisher Scientific) 
to label murine myeloid, CD8+, and human monocytes, respectively. 
Next, the cells were washed and then incubated with anti-biotin 
magnetic beads (Miltenyi Biotec) before performing manual positive 
selection using MS columns (Miltenyi Biotec). Purified cells were 
analyzed for all downstream metabolic analyses.
In vitro T cell/TAMC generation
TAMCs were generated as described previously (9). Briefly, bone 
marrow precursors were isolated from the femurs of C57/Bl6 mice 
or C57 OT-1 mice and resuspended in RPMI supplemented with 
recombinant granulocyte-macrophage colony-stimulating factor (GM-
CSF) (40 ng/ml) and 50% of 0.2-m sterile-filtered CT-2A supernatant. 
After 3 days, cells were washed and replaced with the same medium. 
At 6 days, cells were validated to be phenotypically similar to 
TAMCS in vivo (9). CD8+ T cells were isolated from the spleens of 
mice using a MagniSort CD8+ T cell Enrichment kit (Thermo Fisher 
Scientific) and stimulated with mouse T cell–activating Dynabeads 
(Thermo Fisher Scientific). For antigen-specific activation, we used 
SIINFEKL peptide (50 ng/ml) on OT-1 isolated T cells.
Histological evaluation of tumors
For hematoxylin and eosin (H&E) analysis, tumors were implanted, 
and 5 days after tumor implantation, brains were harvested and fixed 
overnight in 10% neutral buffered formalin overnight. Samples were 
submitted to the Northwestern Pathology Core, where paraffin em-
bedding and H&E staining were performed. Validation of tumor 
engraftment was performed by certified neuropathologist. For 
immunofluorescence, mice were perfused with 10 ml of PBS, and 
brains were snap-frozen in OCT (Sakura Tissue-Tek). Brains were 
then cut into 8-m-thick sections using a CM1860 cryostat (Leica, 
Wetzlar, Germany). Sections were fixed with 100% methanol pre-
chilled at −80°C for 10 min. Sections were blocked in 5% normal rat 
serum for 30  min, washed, and then incubated 1:100 with anti- 
CD8–PE (phycoerythrin) and anti-CD11b–Alexa Fluor 488. Last, 
sections were mounted using Fluoroshield with DAPI (4′,6-diamidino- 
2-phenylindole) (Sigma-Aldrich). Four control and four DFMO- 
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analyzed for infiltration per mouse. Image identities were blinded 
and counted blindly by A.R.
Immunophenotyping
Single-cell suspensions were blocked with anti-CD16/32 antibodies 
before incubation with antibody panels as described below. For cy-
tokine staining, cells were preincubated with phorbol 12-myristate 
13-acetate (PMA)/ionomycin + brefeldin A for 4 hours before fixation 
and intracellular staining. The Foxp3 fixation/permeabilization 
(Invitrogen, Thermo Fisher Scientific) protocol was used for all 
intracellular flow cytometric analysis (71).
The following myeloid panel was used for flow cytometric anal-
ysis: Live/Dead eFluor 780 (Thermo Fisher Scientific), anti-CD45 
BV510, anti-CD3 PE-Cy7, anti-C11b Pacific Blue, anti-Ly6C AF 
700, anti-Ly6G peridinin chlorophyll protein (Percp)–cy5.5, anti–
arginase 1 allophycocyanin (APC), anti–PD-L1 PE, anti-CD11c 
BV605, anti–TGF-–LAP BV711, and anti–interleukin-10 (IL-10) 
fluorescein isothiocyanate (FITC). All antibodies are purchased 
from BioLegend except arginase-1 (Thermo Fisher Scientific).
The following flow cytometry panel was used for lymphocytic 
analysis: Live/Dead eFluor 780, anti-CD45 BV510, anti-CD4 PE-
Cy7, anti-CD8–BV605, anti-CD44 Percpcy5.5, anti-Foxp3 eFluor 
450, anti-CD19 BV711, anti-CD25 PE, anti–interferon  (IFN) AF 
700, anti-TNF FITC, and anti–granzyme B Alexa Fluor 647. All 
antibodies are purchased from BioLegend except Foxp3 (Thermo 
Fisher Scientific). This allows us to define conventional T cells 
(CD45+CD3+CD4+CD8−Foxp3−), regulatory T cells (CD45+CD3+ 
CD4+CD8−Foxp3+CD25+), B cells (CD45+CD3−CD19+), and natural 
killer (NK) cells (CD45+CD3−NK1.1+). IFN, TNF, and granzyme B 
expression are a measure of inflammatory phenotype on each of 
these cells.
The following flow cytometry panel was used for tetramer anal-
ysis: Live/Dead eFluor 780, anti-CD45 BV510, anti-CD4 PE-Cy7, 
anti-CD8 PE (clone KT15 from Medical & Biological Laboratories 
Co.), anti-CD44 Percpcy5.5, anti-Foxp3 eFluor 450, anti-CD11b 
BV711, and anti–SIINFEKL-H2kb tetramer Alexa Fluor 488. The 
conjugated tetramers were generated by the National Institutes of 
Health (NIH) Tetramer Facility at Emory University. Tetramer stain-
ing was performed at room temperature for 45 min.
For pHrodo Red intracellular pH measurement, cells from spleen 
or tumor were counted, normalized, and incubated with 500  nm 
pHrodo Red dye in PBS at 37°C for 30 min before being washed 
twice with 2% FBS/PBS wash buffer. This step was performed be-
fore live/dead and antibody staining as described above.
For cell necrosis/apoptotic measurement, TAMCs were washed 
with PBS before being incubated with live/dead eFluor 780 for 30 min 
on ice. Cells were washed twice with annexin V binding buffer 
(BioLegend) before being incubated with annexin V FITC (1:20; 
BioLegend) for 15 min at room temperature. Cells were then washed 
twice with annexin binding buffer (Becton Dickinson) and kept in 
binding buffer during flow cytometric analysis.
Extracellular flux assays
Extracellular flux analysis on TAMCs was performed using a Seahorse 
XFe96 analyzer (Agilent), as previously described (72). Briefly, 
TAMCS were lifted and adhered to microplates using Cell-Tak 
Adhesive (Thermo Fisher Scientific) at a density of 1 × 105 cells per 
well. Glycolytic flux was measured using the glycolysis stress test 
(Agilent) following the manufacturer’s guidelines.
RNA-seq analysis
Fourteen days after CT-2A tumor implantation, 10 mice were pooled 
for each n reported in this study, followed by Gr1 magnetic bead 
isolation, and RNA was isolated using TRIzol (Thermo Fisher 
Scientific)–based RNA purification. Briefly, 0.2 ml of chloroform 
was added to TRIzol samples; top RNA-containing layer was pre-
cipitated with 70% isopropanol. Pellets were dried, then resuspended 
in sterile water, and sent for analysis. Isolated samples were sent to 
Novogene, which analyzed RNA for quality and provided all data as 
total counts and fpkm (fragments per kilobase per million reads) 
values. Fpkm values are reported throughout this manuscript.
Metabolic flux analyses
Arginine flux
SILAC RPMI medium was supplemented with 10% dialyzed FBS 
(Fisher), glycine (40 mg/ml), and U13C-arginine (200 mg/ml; 
Cambridge Isotope Laboratories). All cells were washed with blank 
SILAC before being reconstituted in 13C medium at a concentration 
of 1 × 106 to 2 × 106 cells/ml for 2 to 4 hours, depending on the 
assay. Cells were lifted and washed twice with PBS before pellets 
were flash-frozen and stored at −80°C until metabolite extraction. 
Pellets were resuspended in 80% methanol/20% H2O and then lysed 
by 3× cycles of heat shock (LN2 freezing followed by 42°C water bath). 
Samples were then spun at 14,000 rpm for 15 min; supernatant was 
collected and analyzed as described below.
Glucose flux
Glucose-free RPMI medium was supplemented with 10% dialyzed 
FBS and U13C-glucose (2 g/liter; Cambridge Isotope Laboratories). 
All cells were washed with blank SILAC before being reconstituted 
in 13C medium at a concentration of 1 × 106 to 2 × 106 cells/ml for 
2 to 4 hours, depending on the assay. Cells were lifted and washed 
twice with PBS before pellets were flash-frozen and stored at −80°C 
until metabolite extraction.
In vivo flux
In vivo glucose flux was performed exactly as described previously 
(42), adapted to our tumor models. Two weeks after tumor implan-
tation (7 days after DFMO administration), mice were continuously 
anesthetized with isoflurane using an anesthetic vaporizer (Harvard 
Apparatus) connected to mouse tail illuminator/restrainer (Braintree 
Scientific). U13C-Glucose was diluted to 100 mg/ml in 0.9% saline 
(Baxter) and loaded into 1-ml Luer-lock syringes (Becton Dickinson). 
Loaded tubes were connected via MicroRenathane tubing (Braintree) 
to a 27-gauge scalp-vein butterfly needle (Exelint International). Mice 
were injected with a 130-l bolus of label, before being infused at a 
rate of 2.5 l/min using a syringe pump (Braintree) for 2.5 hours. 
After infusion, mice were immediately euthanized and tumor, normal 
brain, and liver were flash-frozen in LN2 and stored at −80°C until 
extraction. For metabolite extraction, 50 mg of frozen tissue was 
homogenized in 3 ml of 80% methanol/20% H2O using a Polytron 
homogenizer (Kinematica USA). Homogenized samples were incu-
bated at −80°C overnight and then spun at 14,000 rpm for 15 min; 
supernatant was collected and analyzed as described below.
Normalizations for metabolic data
To ensure rigor of data presented, two independent forms of 
normalization were performed on all samples. For samples that 
involved cellular isolation, we normalized each submission to the 
lowest cell count obtained to ensure uniformity in injection. These 
numbers of cells submitted to LC-MS/MS were always between 5 × 105 
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normalize them across samples (50 mg of tissue was uniformly used). 
The secondary method of normalization is to determine total ion 
count (TIC) and normalize all samples to the lowest TIC reading 
after the LC-MS/MS has been run. This is the gold standard method 
of normalization of MS data (73).
Hydrophilic metabolite profiling
Isolated TAMC and CD8+ T cells samples were dried using a SpeedVac. 
Acetonitrile (50%) was added to the tube for reconstitution follow-
ing overtaxing for 30 s. Sample solution was then centrifuged for 
15 min at 20,000g and 4°C. Supernatant was collected for LC-MS 
analysis. Samples were analyzed by high-performance LC (HPLC) 
and high-resolution MS and MS/MS (HPLC-MS/MS). The system 
consists of Thermo Q Exactive with an electrospray source and an 
UltiMate3000 (Thermo Fisher Scientific) series HPLC consisting of 
a binary pump, degasser, and autosampler outfitted with an XBridge 
Amide column (Waters; dimensions of 4.6 mm by 100 mm and a 
3.5-m particle size). The mobile phase A contained 95% water/5% 
acetonitrile (v/v), 20 mM ammonium hydroxide, and 20 mM 
ammonium acetate (pH 9.0); phase B was 100% acetonitrile. The 
gradient was performed as follows: 0 min, 15% A; 2.5 min, 30% A; 
7 min, 43% A; 16 min, 62% A; 16.1 to 18 min, 75% A; and 18 to 
25 min, 15% A with a flow rate of 400 l/min. The capillary of the 
electrospray ionization source was set to 275°C, with sheath gas at 
45 arbitrary units, auxiliary gas at 5 arbitrary units, and the spray 
voltage at 4.0 kV. In positive/negative polarity switching mode, a 
mass/charge ratio (m/z) scan range from 70 to 850 was chosen and 
MS1 data were collected at a resolution of 70,000. The automatic 
gain control target was set at 1 × 106, and the maximum injection 
time was 200 ms. The top five precursor ions were subsequently 
fragmented, in a data-dependent manner, using the higher-energy 
collisional dissociation cell set to 30% normalized collision energy 
in MS2 at a resolution power of 17,500. Data acquisition and analy-
sis were carried out by Xcalibur 4.1 software and TraceFinder 4.1 
software, respectively (both from Thermo Fisher Scientific).
pHLIP dye measurement of pHe
Mice were intracranially injected with CT-2A or saline. Fourteen 
days after tumor engraftment, 100 l of pHLIP-Cy5.5 dye at 100 M 
(synthesized and provided by Y.K.R.) was administered via intravenous 
injection. Twenty-four hours after injection, brains and spleens from 
both controls and tumor-bearing mice were immediately harvested 
and scanned with a spectral Lago (Spectral Imaging Systems, 
Tucson, AZ) with excitation at 675 nm and emission at 730 nm. The 
fluorescence intensities in regions of interest were calculated using 
Aura Imaging Software.
IncuCyte time-based fluorescence assay
TAMCs were generated and treated with inhibitors DFMO as de-
scribed above. At day 6, cells were labeled with pHrodo Red AM, 
and the same number of cells (1 × 106 cells) was labeled with the 
same concentration of dye before being washed for IncuCyte analy-
sis. TAMCs were resuspended at a concentration of 1 × 105/ml in 
live cell imaging buffer (Thermo Fisher Scientific) at a pH of 7.4, 
7.0, and 6.7. To generate a pH standard curve, TAMCs were pre-
treated with pH 7.4, 7.0, and 6.7 solution containing nigericin/
valinomycin to clamp intracellular pH to extracellular pH. The fluo-
rescence measurement of these standards was used to generate a curve 
by which the experimental groups were measured. The membrane- 
impermeant dye IncuCyte Cytotox Green (Essen Bioscience) was 
added at a 1:1000 dilution to monitor for apoptosis. Cells were im-
aged every 20 min for 4 hours, and fluorescence flux of pHrodo Red 
was measured over time. After 2 hours of measurement, nigericin/
valinomycin was added to experimental wells to measure clamped pH.
Statistical analysis
Statistical significance across two group was determined using two-
tailed unpaired Student’s t test performed on figures with individual 
comparisons. One-way analysis of variance (ANOVA) with Tukey’s 
post hoc was performed for comparisons of three or more groups. 
Kaplan-Meier curves were generated, and log-rank test was performed 
to determine significance of in vivo survival rates. P values were 
calculated in Prism software (GraphPad, San Diego, CA), and the 
significance is as stated in the figure legends. Error bars are shown 
as ±SEMs for all figures. For pHrodo Red analyses, mixed-effects 
models for longitudinal data were performed and post hoc analysis 
was performed in both R and SAS, which produced similar results. 
For MetaboAnalyst data, normalized peak areas were inputted into 
online software, and heatmaps were generated based on t test statistical 
significance. MetaboAnalyst figure was automatically generated by 
the MetaboAnalyst website (74). All statistics were validated by T.X.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/8/eabc8929/DC1
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